Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin to Improve Response to nCRT in Oesophageal Adenocarcinoma
NCT06687876Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs) in esophageal adenocarcinoma (EAC), sponsored by Amsterdam University Medical Center. Started Mar 2025; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT06687876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687876.